Will Rescheduling Hydrocodone Combination Products Actually Reduce Abuse?

Published Online: Thursday, January 16, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.

This is the part of a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)

These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Ludy L. Underwood, Cardinal Health sales manager for retail/alternative care, pharmaceutical division, talks about how Cardinal Health’s Generation Rx program raises awareness of prescription drug abuse.
Teva Pharmaceutical Industries recently announced that the FDA has accepted for review a New Drug Application for its investigational formulation of extended-release hydrocodone bitartrate with abuse-deterrent properties.
ASHP will recognize the achievements of an accomplished group of health care practitioners with the organization’s 2015 Board of Directors’ Awards.
Timothy Aungst, PharmD, assistant professor of pharmacy practice at MCPHS University, talks about how mHealth can improve pharmacy practice.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$